Zhi Tong Cai Jing·2025-12-08 02:11Core Viewpoint - Junshi Biosciences (01877) has seen a stock price increase of over 3%, currently at 24.28 HKD, following the announcement of new indications for its products being included in the National Medical Insurance Directory for 2025 [1] Group 1: Product Developments - The product Toripalimab injection (brand name: Tuoyi®, product code: JS001) has received two new indications [1] - The product Engreztinib injection (brand name: Junshida®, product code: JS002) has successfully been included in the National Medical Insurance Directory [1] - Both products will be officially included in the updated National Medical Insurance Directory effective January 1, 2026 [1] Group 2: Market Position - As of the announcement date, four commercialized products, including Tuoyi®, have been included in the National Medical Insurance Directory [1] - Tuoyi® is the only anti-PD-1 monoclonal antibody in the directory that treats renal cancer, triple-negative breast cancer, and melanoma [1] - Junshida® is the first product to be included in the directory for patients intolerant to statins, marking it as the only domestic PCSK9-targeted drug in the new directory [1]